Feature | March 19, 2013

Lower-Profile Sapien XT Transcatheter Heart Valve Associated With Improved Procedural Outcomes

Preliminary results from inoperable cohort of the PARTNER II Trial presented at ACC 2013

Edward Structural Heart Valve Repair Clinical Trial Sapien XT Transcatheter

March 18, 2013 — Edwards Lifesciences Corporation announced that preliminary results from The PARTNER II clinical trial demonstrated similar one-year outcomes in mortality and major clinical events between the Edwards Sapien XT transcatheter aortic valve and the Edwards SAPIEN valve, yet fewer vascular events with the lower-profile Sapien XT valve. These data from The PARTNER II Trial studying transcatheter aortic valve replacement (TAVR) in inoperable patients with severe, symptomatic aortic stenosis were presented as a late-breaking clinical trial at the American College of Cardiology's (ACC) 62nd Annual Scientific Session in San Francisco.

The PARTNER II Trial enrolled 560 patients deemed inoperable for traditional open-heart surgery at 28 hospitals in the United States between April 2011 and February 2012. Patients were randomized to receive one of the two Edwards transcatheter aortic heart valves: 276 received the Sapien valve, and 284 received the Sapien XT valve.

The U.S. Food and Drug Administration (FDA) approved the Sapien valve in November 2011 for the treatment of inoperable patients, and expanded the indication to high-risk surgical patients in October 2012. The Sapien XT valve is an investigational device not yet available commercially in the United States.

Edwards anticipates submitting data from the inoperable cohort (Cohort B) of The PARTNER II Trial to the FDA in the second quarter. The company expects to complete enrollment in the intermediate risk cohort (Cohort A) of The PARTNER II Trial mid-year.

For more information: www.edwards.com

Related Content

CardioKinetix, Parachute device, heart failure, 500th implantation, PARACHUTE IV Trial
News | Heart Failure| July 22, 2016
CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning...
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign, Trialign system, tricuspid regurgitation. SCOUT U.S. study, phase 1 enrollment
News | Heart Valve Technology| July 19, 2016
Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the...
Sponsored Content | Videos | Computed Tomography (CT)| July 08, 2016
An interview with Jonathan Leipsic, M.D., FSCCT, chairman of the department of radiology, St.
AtriCure, AtriClip PRO2 LAA Exclusion System, CE Mark, left atrial appendage occlusion
News | Left Atrial Appendage (LAA) Occluders| July 05, 2016
AtriCure Inc. announced that it has received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System...
ASE 2016, echo, echocardiography, cardiac ultrasound, annual meeting, ASE.16, American Society of Echocardiography
Feature | Cardiovascular Ultrasound| July 01, 2016
Below is a round up of news and videos about new cardiac ultrasound technology discussed in sessions and on the expo
Cormatrix Cardiovascular, Tyke ECM, extracellular matrix, neonates and infants
News | Congenital Heart| June 30, 2016
CorMatrix Cardiovascular Inc. announced the treatment of the first patients using its CorMatrix Tyke, a product...
Sponsored Content | Videos | Structural Heart| June 30, 2016
Interview with Steven Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and V
Overlay Init